g8 发帖数: 3784 | 1 The first new treatment for lupus in a half-century won U.S. approval on
Wednesday, a milestone for patients with the disabling disease and a
potential blockbuster for tiny biotech company Human Genome Sciences.
Health officials cleared Benlysta for certain patients with active lupus who
are receiving standard therapy. The disease causes the immune system to
attack joints and organs and has proved tough to study and treat.
Human Genome will split profits from the drug with GlaxoSmithKline.
In clinical trials, black patients "did not appear to respond to treatment,"
the FDA said. To address that concern, the company will run another study
to further examine safety and effectiveness in black patients, the agency
said.
Benlysta's annual global sales may top $3 billion in 2015, according to
Thomson Reuters consensus forecasts. |
|